PS
LGND icon

Principal Securities’s Ligand Pharmaceuticals LGND Stock Holding History

Principal Securities’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$202K Sell
1,010
-117
-10% -$23.1K ﹤0.01% 1383
2025
Q4 		$213K Buy
1,127
+793
+237% +$152K ﹤0.01% 1299
2025
Q3 		$59.2K Buy
334
+58
+21% +$8.62K ﹤0.01% 1873
2025
Q2 		$31.4K Buy
276
+101
+58% +$10.8K ﹤0.01% 2099
2025
Q1 		$18.8K Hold
175
– – ﹤0.01% 2230
2024
Q4 		$18.8K Sell
175
-23
-12% -$2.6K ﹤0.01% 2228
2024
Q3 		$19.8K Buy
198
+151
+321% +$15.2K ﹤0.01% 2129
2024
Q2 		$3.96K Sell
47
-190
-80% -$15.1K ﹤0.01% 2714
2024
Q1 		$17.3K Sell
237
-510
-68% -$37.6K ﹤0.01% 2075
2023
Q4 		$53.4K Buy
+747
New +$44.1K ﹤0.01% 1454

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Principal Securities's LGND Position: Q1 2026 in Review

Principal Securities reduced its Ligand Pharmaceuticals (LGND) stake by 10% in Q1 2026, selling an estimated $23.1K and leaving 1,010 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #1383.

Principal Securities first reported a position in LGND in Q4 2023 and has held it in 10 quarters since. The position peaked at $213K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Principal Securities held 1,010 shares of Ligand Pharmaceuticals worth $202K as of Q1 2026.
  • Principal Securities sold 117 Ligand Pharmaceuticals shares in Q1 2026, an estimated $23.1K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Principal Securities's portfolio in Q1 2026, its #1383 holding.
  • Principal Securities first reported a position in Ligand Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Principal Securities's Ligand Pharmaceuticals position peaked at $213K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Principal Securities's 13F filing for Q1 2026, filed 13 May 2026.